Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XMAB22841 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Xencor
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**XMAB22841 + pembrolizumab** is an investigational combination therapy consisting of XmAb22841, a humanized bispecific monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and lymphocyte-activation gene 3 (LAG3), paired with pembrolizumab, an approved monoclonal antibody targeting programmed cell death protein 1 (PD-1). XmAb22841 is designed to block immune checkpoints within the tumor microenvironment, enhancing T cell activation against tumor cells. Pembrolizumab blocks PD-1 on T cells, further promoting anti-tumor immune response. This combination is being evaluated for safety, tolerability, and anti-tumor activity in subjects with advanced solid tumors, including advanced/metastatic melanoma[1][3][4][5][6].
- Brand names
- Keytruda
- Other names
- XmAb22841XmAb-22841XmAb 22841pembrolizumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on XMAB22841 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XMAB22841 + pembrolizumab.